FATE News and Press, Fate Therapeutics Inc. From 11/13/25

2025-11-13 09:34:13 ET More on Fate Therapeutics Fate Therapeutics: Recent Update Met With Selling, But Positives Exist Seeking Alpha’s Quant Rating on Fate Therapeutics Historical earnings data for Fate Therapeutics Financial information for Fate Ther...

Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate that Utilizes Less-intensive or No Conditioning, Enabling Broad Patient Accessibility Fi...

Ensysce Biosciences Inc. (ENSC) is expected to report $-0.85 for Q3 2025 IO Biotech Inc. (IOBT) is expected to report $-0.31 for Q3 2025 Lifeward Ltd. (LFWD) is expected to report $-0.14 for Q3 2025 Life360 Inc. (LIF) is expected to report $0.03 for Q3 2025 Pixelworks Inc. (PXLW) ...

As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or no conditioning chemotherapy Favorable safety profile with no dose-limiting toxicities...

2025-10-14 08:15:40 ET More on Fate Therapeutics Fate Therapeutics: Recent Update Met With Selling, But Positives Exist Seeking Alpha’s Quant Rating on Fate Therapeutics Historical earnings data for Fate Therapeutics Financial information for Fate Ther...

SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE) (the Company), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the ap...

2025-08-29 17:43:11 ET ... Read the full article on Seeking Alpha For further details see: Fate Therapeutics: Recent Update Met With Selling, But Positives Exist

SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, announced that the Co...

2025-08-14 11:27:33 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fi...

2025-08-12 16:45:29 ET More on Fate Therapeutics Seeking Alpha’s Quant Rating on Fate Therapeutics Historical earnings data for Fate Therapeutics Financial information for Fate Therapeutics Read the full article on Seeking Alpha For further det...